Australia's largest stock trading and investment forum Australia's #1 stock forum

NOX

5.41%

7.0¢ noxopharm limited

These results are outstanding. Good luck.

First 16 Last

Share
Profile

Follow
beefarmer

15,355 Posts.

1413

21/11/17

13:54

Post #: 28985384
Share
Originally posted by timke ↑

Hi guys, here's an email I was forwarded from a broker

Noxopharm is encouraged by today’s ASX announcement providing data from ESMO Asia 2017, bearing in mind that this is interim data.

In summary, in a majority of patients treated and reviewed to this point, a combination of NOX66 and (low dose ) carboplatin appears to be halting the progression of late-stage cancer in 5 different cancer types.

To understand the basis of that encouragement, it might help to understand what the Company is hoping to achieve out of the study.

The majority of patients with solid cancers (breast, prostate, lung, ovary, melanoma etc) that become metastatic (develop secondaries), eventually become resistant to therapies, and in most of these cases, death almost inevitably will follow.

There are also the elderly and frail patients where it is considered too risky and too damaging to treat them with standard therapies.

There is also a group of people who decline chemotherapy, knowing that the chance of responding comes often with damaging side-effects.

Noxopharm hopes to offer all those patients the potential of a chance of extended survival, without toxic side-effects.

The study reported on today is looking for some evidence that NOX66 can achieve this. The aim is to use NOX66 to make a low dose of a common chemotherapy drug (too low to have any anti-cancer effect on its own, but low enough to be well tolerated), turn into a more powerful drug. The uniqueness of NOX66 lies in the fact that it only works on cancer cells, so that means that it boosts the effect of the chemotherapy drug only on cancer cells and not on healthy cells.

The data in summary:

The study is using patients with late-stage (Stage 4) cancers. They have metastatic cancer (multiple secondaries). They have failed all standard treatment options.

Current effect appears to be achieved across a range of common cancers, not just a single cancer type.

17 patients treated with NOX66 and a low-dose of the chemotherapy drug, carboplatin.

The dose of carboplatin is predicted to be low enough to not cause any serious side-effects, but too low to provide any worthwhile anti-cancer effect.

11 of the 17 patients have completed 3 months of treatment of NOX66 + low dose carboplatin and have had their cancer assessed by scans.

9 of the 11 have shown no disease progression.

1 of the 11 showed partial response ( ie no new lesions, >30% shrinkage of the sum of the longest diameters of the target tumours).

Of the 11 patients, only 1 has shown disease progression.

None of the 11 patients have recorded any serious side-effects.

Expand

These results are outstanding.

Good luck.
NOX Price at posting: 82.0¢ Sentiment: Buy Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

BGL

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

PEC

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

MM1

Geochemical work at Newington picks up gold and copper anomalies for Midas

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

There are more pages in this discussion • 2 more messages in this thread...

First 16 Last

Add NOX (ASX) to my watchlist

(20min delay)
Last 7.0¢		Change -0.004(5.41%)		Mkt cap ! $20.45M

Open	High	Low	Value	Volume
7.3¢	7.3¢	7.0¢	$3.155K	43.55K

Buyers (Bids)

No.	Vol.	Price($)
1	22000	7.0¢

Sellers (Offers)

Price($)	Vol.	No.
7.4¢	50000	1

View Market Depth

No.	Vol.	Price($)
2	14000	0.068
1	1672	0.066
1	15000	0.065
1	79000	0.063
1	100000	0.062

Price($)	Vol.	No.
0.074	50000	1
0.076	4999	1
0.079	12000	1
0.080	100000	1
0.081	22345	2

Last trade - 15.50pm 25/07/2024 (20 minute delay)

NOX (ASX) Chart

These results are outstanding. Good luck.

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Geochemical work at Newington picks up gold and copper anomalies for Midas

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

These results are outstanding. Good luck.

Top Stories

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Geochemical work at Newington picks up gold and copper anomalies for Midas

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News